Literature DB >> 30775991

Vascular Burden Score Impacts Cognition Independent of Amyloid PET and MRI Measures of Alzheimer's Disease and Vascular Brain Injury.

Charles DeCarli1, Sylvia Villeneuve2, Pauline Maillard1, Danielle Harvey3, Baljeet Singh1, Owen Carmichael4, Evan Fletcher1, John Olichney1, Sarah Farias1, William Jagust5, Bruce Reed6, Dan Mungas1.   

Abstract

BACKGROUND/
OBJECTIVE: To determine the impact of vascular burden on rates of decline in episodic memory and executive function. We hypothesize that greater vascular burden will have an additive negative impact on cognition after accounting for baseline cognitive impairment, positron emission tomography (PET) amyloid burden, and magnetic resonance imaging (MRI) measures.
METHODS: Individuals were followed an average of 5 years with serial cognitive assessments. Predictor variables include vascular burden score (VBS), quantitative brain MRI assessment, and amyloid imaging. Subjects consisted of 65 individuals, 53% of whom were male, aged 73.2±7.2 years on average with an average of 15.5±3.3 years of educational achievement.
RESULTS: Baseline cognitive impairment was significantly associated poorer episodic memory (p < 0.0001), smaller hippocampal volume (p < 0.0001), smaller brain volume (p = 0.0026), and greater global Pittsburg Imaging Compound B (PiB) index (p = 0.0008). Greater amyloid burden was associated with greater decline in episodic memory over time (β= -0.20±0.07, p < 0.005). VBS was significantly associated with the level of executive function performance (β= -0.14±0.05, p < 0.005) and there was a significant negative interaction between VBS, cognitive impairment, and PiB index (β= -0.065±0.03, p = 0.03).
CONCLUSIONS: Our results find a significant influence of VBS independent of standard MRI measures and cerebral amyloid burden on executive function. In addition, VBS reduced the amount of cerebral amyloid burden needed to result in cognitive impairment. We conclude that the systemic effects of vascular disease as reflected by the VBS independently influence cognitive ability.

Entities:  

Keywords:  Alzheimer’s disease; cerebrovascular disorders; cognition; neuroimaging

Mesh:

Year:  2019        PMID: 30775991      PMCID: PMC6615551          DOI: 10.3233/JAD-180965

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  50 in total

Review 1.  Inflammation, atherosclerosis, and coronary artery disease.

Authors:  Göran K Hansson
Journal:  N Engl J Med       Date:  2005-04-21       Impact factor: 91.245

2.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2013-02       Impact factor: 44.182

3.  Association of Aortic Stiffness With Cognition and Brain Aging in Young and Middle-Aged Adults: The Framingham Third Generation Cohort Study.

Authors:  Matthew P Pase; Jayandra J Himali; Gary F Mitchell; Alexa Beiser; Pauline Maillard; Connie Tsao; Martin G Larson; Charles DeCarli; Ramachandran S Vasan; Sudha Seshadri
Journal:  Hypertension       Date:  2016-01-11       Impact factor: 10.190

4.  Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

Authors:  Julie C Price; William E Klunk; Brian J Lopresti; Xueling Lu; Jessica A Hoge; Scott K Ziolko; Daniel P Holt; Carolyn C Meltzer; Steven T DeKosky; Chester A Mathis
Journal:  J Cereb Blood Flow Metab       Date:  2005-11       Impact factor: 6.200

5.  Distribution volume ratios without blood sampling from graphical analysis of PET data.

Authors:  J Logan; J S Fowler; N D Volkow; G J Wang; Y S Ding; D L Alexoff
Journal:  J Cereb Blood Flow Metab       Date:  1996-09       Impact factor: 6.200

6.  Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study.

Authors:  Tom Jeerakathil; Philip A Wolf; Alexa Beiser; Joseph Massaro; Sudha Seshadri; Ralph B D'Agostino; Charles DeCarli
Journal:  Stroke       Date:  2004-06-24       Impact factor: 7.914

7.  Associations between serum cholesterol levels and cerebral amyloidosis.

Authors:  Bruce Reed; Sylvia Villeneuve; Wendy Mack; Charles DeCarli; Helena C Chui; William Jagust
Journal:  JAMA Neurol       Date:  2014-02       Impact factor: 18.302

8.  Association of Serum Docosahexaenoic Acid With Cerebral Amyloidosis.

Authors:  Hussein N Yassine; Qingru Feng; Ida Azizkhanian; Varun Rawat; Katherine Castor; Alfred N Fonteh; Michael G Harrington; Ling Zheng; Bruce R Reed; Charles DeCarli; William J Jagust; Helena C Chui
Journal:  JAMA Neurol       Date:  2016-10-01       Impact factor: 18.302

9.  Vascular risk at younger ages most strongly associates with current and future brain volume.

Authors:  Matthew P Pase; Kendra Davis-Plourde; Jayandra J Himali; Claudia L Satizabal; Hugo Aparicio; Sudha Seshadri; Alexa S Beiser; Charles DeCarli
Journal:  Neurology       Date:  2018-09-19       Impact factor: 11.800

10.  Comparison of cerebral blood flow and structural penumbras in relation to white matter hyperintensities: A multi-modal magnetic resonance imaging study.

Authors:  Nutta-On Promjunyakul; David L Lahna; Jeffrey A Kaye; Hiroko H Dodge; Deniz Erten-Lyons; William D Rooney; Lisa C Silbert
Journal:  J Cereb Blood Flow Metab       Date:  2016-06-07       Impact factor: 6.200

View more
  7 in total

1.  Plasma total-tau as a biomarker of stroke risk in the community.

Authors:  Matthew P Pase; Jayandra J Himali; Hugo J Aparicio; Jose Rafael Romero; Claudia L Satizabal; Pauline Maillard; Charles DeCarli; Alexa S Beiser; Sudha Seshadri
Journal:  Ann Neurol       Date:  2019-07-29       Impact factor: 10.422

2.  Particulate matter and episodic memory decline mediated by early neuroanatomic biomarkers of Alzheimer's disease.

Authors:  Diana Younan; Andrew J Petkus; Keith F Widaman; Xinhui Wang; Ramon Casanova; Mark A Espeland; Margaret Gatz; Victor W Henderson; JoAnn E Manson; Stephen R Rapp; Bonnie C Sachs; Marc L Serre; Sarah A Gaussoin; Ryan Barnard; Santiago Saldana; William Vizuete; Daniel P Beavers; Joel A Salinas; Helena C Chui; Susan M Resnick; Sally A Shumaker; Jiu-Chiuan Chen
Journal:  Brain       Date:  2020-01-01       Impact factor: 13.501

Review 3.  Cerebral Hypoxia: Its Role in Age-Related Chronic and Acute Cognitive Dysfunction.

Authors:  Brina Snyder; Stephanie M Simone; Tania Giovannetti; Thomas F Floyd
Journal:  Anesth Analg       Date:  2021-06-01       Impact factor: 6.627

4.  Association of a Total Cholesterol Polygenic Score with Cholesterol Levels and Pathological Biomarkers across the Alzheimer's Disease Spectrum.

Authors:  Nathalie I V Nilsson; Cynthia Picard; Anne Labonté; Theresa Köbe; Pierre-François Meyer; Sylvia Villeneuve; Daniel Auld; Judes Poirier
Journal:  Genes (Basel)       Date:  2021-11-17       Impact factor: 4.096

5.  Associating Type 2 Diabetes Risk Factor Genes and FDG-PET Brain Metabolism in Normal Aging and Alzheimer's Disease.

Authors:  Scott Nugent; Olivier Potvin; Stephen C Cunnane; Ting-Huei Chen; Simon Duchesne
Journal:  Front Aging Neurosci       Date:  2020-10-30       Impact factor: 5.750

6.  Association of vascular brain injury, neurodegeneration, amyloid, and cognitive trajectory.

Authors:  Ji Won Han; Pauline Maillard; Danielle Harvey; Evan Fletcher; Oliver Martinez; David K Johnson; John M Olichney; Sarah T Farias; Sylvia Villeneuve; William Jagust; Dan Mungas; Charles DeCarli
Journal:  Neurology       Date:  2020-07-30       Impact factor: 9.910

Review 7.  Cerebral Small Vessel Disease in Sporadic and Familial Alzheimer Disease.

Authors:  Rajesh N Kalaria; Diego Sepulveda-Falla
Journal:  Am J Pathol       Date:  2021-07-28       Impact factor: 4.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.